Resolve Digital Health Takes Aim at the Opioid Epidemic
January 11th, 2018
Exclusive, News, Top Story
The opioid epidemic has reached catastrophic proportions, especially in the United States. In fact, the U.S. Centers for Disease Control and Prevention report that drug overdoses are now the leading cause of death for Americans under 50. Despite some of the highest spending in the world on medical care, opioid addiction and overdose deaths have taken a big toll on younger and middle-aged Americans. More than 42,000 Americans died of opioid overdoses in 2016 alone, which was up 28% year over year.
In this article, we will look at the growing opioid epidemic and how Resolve Digital Health Inc. plans to address the problem through a series of robust clinical trials.
Growing Opioid Epidemic
According to GBI Research, the U.S. market accounts for 70% of the global demand for prescription opioids and is slated to grow from about $11 billion in 2014 to $17.7 billion in 2021. The pharmaceutical industry continues to push opioids as one of the most profitable classes of drugs ever created despite the acknowledged risk of addiction and overdose.
At the same time, many in the emerging medical marijuana industry believe that cannabis can be an effective and safer alternative for pain management. The medical community has been hesitant to prescribe medical cannabis as a substitute due in large part to the lack of clinical trials. This is a problem Resolve Digital Health plans on addressing.
Resolve’s New Research
Resolve Digital Health recently announced that it began designing the protocols for a series of 12 studies examining the safety and efficacy of its Smart Inhaler medical cannabis formulations compared to commonly-prescribed oxycodone-based prescription drugs, such as OxyContin® and Percocet®. In addition, the company will explore methods of treating opioid addiction and managing chronic pain in conjunction with opioids in the studies.
Mr. Joseph Reiz was appointed to Director of Clinical Research to spearhead these programs, which are set to launch in early 2018. With 28 years of clinical research management experience, Mr. Reiz was formerly the Director of Clinical Research at Purdue Pharma Canada where he had a proven record of overseeing successful conception, planning, and running of large clinical trial programs in the United States and Canada for product approval.
“Through a robust program of research, I look forward to advancing understanding of medical cannabis’ therapeutic value among patients and healthcare practitioners, and helping to pave the way for medical cannabis to reduce the burden on clinicians and health care systems across the continent,” said Mr. Reiz in a recent press release.
An Innovative Solution
Resolve Digital Health has developed a proprietary technology, apps, and a cloud-based health information platform to create a new standard of cannabis care. Its AI driven smart inhaler gathers real-time data from patients, including medical conditions, prescriptions, family histories, and lifestyles to suggest personalized dosing to the patient. Resolve’s app will also share information with the patient’s physician, building a collaborative care model.
Resolve aims to use its platform and research to reduce the reliance on opioids. CEO Rob Adelson stated, “We are invested in achieving widespread acceptance of the use of cannabis-based treatments as an alternative to, or in conjunction with, more traditional pain management therapies. Our Smart Inhaler platform, and the comprehensive data it provides, will be crucial in constructing and completing our studies. We believe that, by combining medical standards and protocols with our data-sharing and personalized dosing capabilities, we can provide an effective and much safer alternative to opioids.”
With the U.S. market for opioid prescriptions expected to grow over 60% to $17.7 billion between 2014 and 2021, alternative pain management options not only represent a valuable social service but a large financial opportunity for companies like Resolve.
Over the past year, the company also announced a series of strategic relationships with leaders in the medical cannabis industry. Aphria Inc. has agreed to provide cannabis to fill Resolve’s proprietary delivery pods and cartridges for sale to the Canadian cannabis market, while Liberty Health Sciences has exclusive distribution rights within the State of Florida. Most recently, Resolve has signed LOI’s with partners in Oregon and Washington, further expanding it’s US distribution.
If you’re interested in learning more about Resolve Digital Health, visit http://promo.cfnmedia.com/breeze to request more information.
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.